Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.

Oncotarget - 27 Jun 2017

Saffroy Raphaël, Fallet Vincent, Girard Nicolas, Mazieres Julien, Sibilot Denis Moro, Lantuejoul Sylvie, Rouquette Isabelle, Thivolet-Bejui Françoise, Vieira Thibaut, Antoine Martine, Cadranel Jacques, Lemoine Antoinette, Wislez Marie

Abstract excerpt

MET exon 14 splicing mutations are new targetable oncogenic drivers reported in 3% of non-small cell lung cancer (NSCLC) cases and have been shown to be more common in pulmonary sarcomatoid carcinomas (PSCs). This study sought to screen mutations affecting MET exon 14 splice sites in a large SC cohort of Caucasian patients, with a large adenocarcinoma cohort as internal control.We tested 81 patients with SC and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins c-met

Share to RNA Splicing

Source

Open in PubMed Open full text

Identifiers

PMID: 28418914
DOI: 10.18632/oncotarget.16403
PMCID: PMC5522077

Genes

MET
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.PMID 28418914Read ↗

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.Semantic proximity Read ↗

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.Semantic proximity Read ↗

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySemantic proximity Read ↗

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.Semantic proximity Read ↗

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable <i>MET</i> Gene MutationsSemantic proximity Read ↗

MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.Semantic proximity Read ↗

Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung CancerSemantic proximity Read ↗

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experienceSemantic proximity Read ↗

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.